||Acarbose is an inhibitor of α-Glucosidases with antihyperglycemic activity.
||Oxfendazole, a broad spectrum benzimidazole anthelmintic,protects livestock against roundworm, strongyles and pinworms.
||PFK-015 is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).
||LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
||PFK-158 is an effective and specific inhibitor PFKFB3.
||3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor.
||AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394 increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal
||Kaempferitrin has antidepressant-like effect related to the serotonergic system, principally 5-HT1A. Kaempferitrin exerts cytotoxic and antitumor effects against HeLa cells. Kaempferitrin stimulates glucose-metabolizing enzymes, promotes glucose homeostasis. Kaempferitrin exerts immunostimulatory e
||Eleutheroside A (Daucosterol) has proliferation-enhancing activity, may be involved in the IGF1-AKT pathway. Daucosterol has efficient and inexpensive neuroprotectant effect, to contribute to IGF1-like activity, could be potentially developed as a medicine for ischemic stroke treatment.
||Genz 123346 is an inhibitor of GL1 synthase that blocks the conversion of ceramide to GL1.
||Voglibose, an N-substituted derivative of valiolamine, exhibits excellent inhibitory activity against α-glucosidases and action against hyperglycemia and various disorders caused by hyperglycemia.
||AP-III-a4 (ENOblock) is the first nonsubstrate analogue inhibitor of enolase with IC50 of 0.576 μM.
||LTI-291 is a glucocerebrosidase (Gcase) activator.